Last reviewed · How we verify
NCT05482464
Effect of Daily Consumption of Glycomacropeptide on Gut Microbiome and Blood Functional Proteome of Subjects With Irritable Bowel Syndrome
NA trial testing Casein glycomacropeptide (CGMP) in Inflammatory Bowel Syndrome in 15 participants. Completed in 1 September 2024.
1 September 2024
Quick facts
| Lead sponsor | Oregon State University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 15 |
| Start date | 1 January 2022 |
| Primary completion | 1 September 2024 |
| Estimated completion | 1 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Casein glycomacropeptide (CGMP)
Conditions studied
- Inflammatory Bowel Syndrome — all drugs for Inflammatory Bowel Syndrome →
Sponsor
Oregon State University
Who can join
Adults 18 to 30, any sex, with Inflammatory Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates the use of glycomacropeptide (GMP) as a means to manipulate the gut microbiome, metabolome and protein profile of subjects with irritable bowel syndrome (IBS).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluating the Potential of Casein Glycomacropeptide in Adult Irritable Bowel Syndrome Management: A Pilot Study.
Qu Y, Park SH, Dallas DC. · · 2023 · cited 3× · PMID 37836457 · DOI 10.3390/nu15194174
Verify or expand the search:
- PubMed search for NCT05482464
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Casein glycomacropeptide (CGMP)
Trials testing the same drug.
- NCT02825914 — CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM) · NA · completed
Other recruiting trials for Inflammatory Bowel Syndrome
Currently open trials in the same condition.
- NCT06810518 — ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool · recruiting
Other Oregon State University trials
Trials by the same sponsor.
- NCT06384742 — Shift Worker Intervention for Sleep Health · NA · recruiting
- NCT05965609 — Optimizing Sleep Health in Nurses · NA · completed
- NCT05950672 — Development and Evaluation CAT and Youth · NA · completed
- NCT06915129 — The Effect of Galactooligosaccharides (GOS) on the Gut Microbiota of Lactose Intolerance Individuals · NA · completed
- NCT04806724 — Opening the Conversation Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05482464 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oregon State University
- Last refreshed: 4 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05482464.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing